MaryMahoneyRuisiMD

Pediatric Hematology & Oncology • New York, NY

Physician

Join to view full profile

Dr. Ruisi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ruisi's full profile

Already have an account?

Office
435 E 70th St
Apartment 11F
New York, NY 10021
Phone+1 212-933-4627

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2008 - 2011
New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2005 - 2008
Icahn School of Medicine at Mount SinaiClass of 2005

Certifications & Licensure

MA State Medical License 2018 - 2026
NJ State Medical License 2012 - 2025
NY State Medical License 2006 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

373 citations
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D'Angelo, James Larkin, Jeffrey A. Sosman, Céleste Lebbé, Benjamin Brady
Journal of Clinical Oncology. 2017-01-10
315 citations
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
Fabrice Barlesi, Johan Vansteenkiste, David R. Spigel, Hidenobu Ishii, Marina Chiara Garassino
The Lancet. Oncology. 2018-11-01
253 citations
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S. Weber, Geoff Gibney, Ryan J. Sullivan, Jeffrey A. Sosman, Craig L. Slingluff
The Lancet. Oncology. 2016-07-01

Abstracts/Posters

Markedly Reduced Expression of Annexin A2 Is Associated with Hypofibrinolysis and Provoked and Unprovoked Venous Thromboembolism
Mary Ruisi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Investigators Find New Cause of Inherited Predisposition to Blood ClotsMay 25th, 2021